+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
E

Actively Recruiting

This research aims to evaluate the safety and effectiveness of Cardiac Contractility Modulation CCM therapy in patients with heart failure who have a left ventricular ejection fraction LVEF between 40% and 70%. The study is a randomized, quadruple-blind, sham-controlled trial conducted at multiple centers across the US and internationally. It includes two parts with distinct scientific goals the first part focuses on functional capacity and health status, while the second part focuses on clinical outcomes. Participants will have the OPTIMIZER Smart Mini System implanted. They will be randomly assigned in a 21 ratio to either receive active CCM therapy CCM ON or a sham treatment with the device turned off CCM OFF during the first 18 months. CCM therapy involves seven one-hour treatment phases spaced evenly over 24 hours daily. After the 18-month blinded phase, those in the sham group will have CCM therapy turned on for the remainder of the study. The trial will enroll about 1500 subjects in total and follow them for up to 18 months or longer through both parts. Participants will undergo screening and baseline tests before implantation. Researchers will monitor their functional capacity using the 6-minute walk test and assess health status with the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety will be tracked by recording device- or procedure-related complications within the first year. Clinical outcomes including mortality and morbidity will be evaluated over 18 months. Follow-up visits and data collection will continue through the study duration to assess these measures and the long-term safety and effectiveness of CCM therapy.

Age: 18Years +All GendersPhase Not Applicable
67 locations
O

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of CCM therapy in treating heart failure in a real-world setting. This global, observational study includes both prospective and retrospective patients who have received or will receive CCM therapy using Impulse Dynamics systems, including future technologies such as CCM-D. Participants will be followed for at least 5 years to gather comprehensive data. Participants receive CCM therapy through an Impulse Dynamics device as part of their regular care. The study does not assign treatments but observes patients who have been implanted or will be implanted with these devices. The registry collects data from multiple centers worldwide, tracking outcomes over time without altering the standard treatment process. During the study, participants will be monitored regularly to assess hospitalizations related to heart failure, device- or procedure-related complications, mortality, functional capacity, and quality of life among other measures. Assessments include questionnaires like the Kansas City Cardiomyopathy Questionnaire and evaluations of clinical outcomes, device compliance, and cardiovascular changes. Follow-up will last for at least five years, ensuring long-term safety and effectiveness data collection.

Age: 18Years +All Genders
30 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of inclisiran, a subcutaneous injection given twice yearly, in preventing major cardiovascular and limb events in patients who have undergone percutaneous coronary or peripheral endovascular revascularization. This phase 4, randomized, double-blind, placebo-controlled study involves about 6,000 participants with symptomatic atherosclerotic cardiovascular disease, including coronary artery disease and peripheral artery disease. The goal is to understand how inclisiran can be used alongside usual care in real-world clinical settings. Participants will receive either inclisiran sodium 300 mg or a matching placebo by subcutaneous injection on Day 1, Month 3 Day 90, and every 6 months thereafter. Treatment starts within 14 days after a successful coronary or peripheral endovascular intervention. Both groups will continue their usual care as directed by their physicians. The study is event-driven and will continue until about 2,380 major events have occurred, with a treatment duration of up to approximately 45 months and an average follow-up of about 36 months. Throughout the study, participants will be regularly monitored for major adverse cardiovascular events and limb events, as well as other outcomes such as cardiovascular death, all-cause death, and venous thromboembolic events. Follow-up will last around 4 years. Assessments include clinical evaluations and ongoing observation to measure the impact of inclisiran compared to placebo while ensuring participant safety and adherence to the study protocol.

Age: 18Years +All GendersPhase 4
149 locations
R

Actively Recruiting

Researchers are collecting real-world data to evaluate the safety and long-term effectiveness of catheter ablation using novel CARTO technologies for treating people with paroxysmal atrial fibrillation PAF, persistent atrial fibrillation PsAF, and ventricular arrhythmias VA. This observational registry gathers information from patients treated with commercially approved Biosense Webster, Inc. ablation catheters at various clinical centers. The goal is to understand clinical outcomes such as procedural efficiency, safety, and arrhythmia recurrence over time. Participants receive catheter ablation treatment following their healthcare providers standard care practices using CARTO systems like THERMOCOOL SMARTTOUCH SF, QDOT MICRO, and VARIPULSE. Future new technologies, including thermal or pulsed field ablation methods, may also be included as they become available. The registry has two groups one for subjects with symptomatic PAF or PsAF considered candidates for atrial fibrillation ablation, and another for subjects with documented ventricular arrhythmias suitable for ablation. During the study, researchers collect baseline and follow-up data based on routine clinical visits without additional procedures required by the registry. They track outcomes such as freedom from arrhythmia recurrence after a 90-day blanking period, serious complications within 7 to 30 days post-ablation, arrhythmia symptoms, medication use, and patient-reported quality of life measures. The total follow-up period extends up to at least 12 months to assess long-term safety and effectiveness of the catheter ablation procedures.

Age: 18Years +All Genders
75 locations
P

Actively Recruiting

Researchers are evaluating the effects of etripamil nasal spray NS compared to placebo in patients who have atrial fibrillation AF with rapid ventricular rate RVR. This is a multi-national, multi-center, randomized, double-blind, placebo-controlled phase 3 study aiming to assess how well etripamil works in this condition. The study includes several phases such as screening, randomization, treatment, follow-up visits, a final study visit, and a telephone follow-up at the end. Participants are randomly assigned to receive either placebo or 70 mg of etripamil NS. They will self-administer the study drug during episodes of AF with RVR, starting with an initial dose and possibly a second dose 10 minutes later if symptoms continue. Patients may treat up to four episodes during the study. The study drug is given as a nasal spray, and the placebo formulation is designed to match the pH of the active drug. Participants will be involved in screening procedures including physical exams, vital signs, ECGs, and lab tests. During the treatment period, they will use ECG cardiac monitoring devices and report symptoms electronically. Monthly follow-up visits and post-treatment visits will monitor safety, collect information on any additional medical interventions, and ensure ongoing eligibility. The final study visit and a telephone follow-up approximately 30 days later will complete the study monitoring. The primary outcome is to measure the efficacy of etripamil within 30 minutes of the first dose.

Age: 18Years +All GendersPhase 3
15 locations
S

Actively Recruiting

Researchers are evaluating the effect of spironolactone combined with standard care compared to standard care alone in patients with Heart Failure with Preserved Ejection Fraction HFPEF. This condition is common and serious, but currently lacks effective treatment. The trial is a phase 3 Registry-Randomized Clinical Trial RRCT involving patients from the Swedish Heart Failure Registry and the US. HFPEF is defined by heart failure symptoms, elevated NT-proBNP levels, and an ejection fraction of 40% or higher. Participants will be randomly assigned to receive either spironolactone added to their usual care or usual care alone. Spironolactone will be given as 25 mg tablets, starting at 25 mg per day with a possible increase to 50 mg daily if tolerated. If spironolactone is not tolerated, eplerenone may be prescribed instead. The control group will continue with their standard care without spironolactone. The study duration is planned for 9 years, with enrollment lasting 7 years. During the study, researchers will collect data on cardiovascular death and hospitalizations due to heart failure as the primary outcomes. Secondary outcomes include hospitalizations for various causes, adverse events, and treatment adherence. In Sweden, outcomes will be obtained by linking national registries, while in the US, sites and call centers will report outcomes. The trial aims to enroll approximately 2000 patients, with follow-up continuing for at least 5 years after study start to monitor these outcomes.

Age: 50Years - 99YearsAll GendersPhase 3
78 locations